Roth Capital Initiates Sucampo Pharmaceuticals At Buy

Roth Capital initiated coverage on shares of Sucampo Pharmaceuticals

with a Buy rating. The target price for Sucampo Pharmaceuticals is set to $9. Sucampo Pharmaceuticals shares have dropped 4.53% over the past 52 weeks, while the S&P 500 index has gained 12.93% in the same period. Sucampo Pharmaceuticals' shares dropped 4.22% to close at $5.90 yesterday.